Verve Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Verve TherapeuticsDie Umsatzerlöse und Gewinne des Unternehmens werden voraussichtlich um 13.6% bzw. 11.6% pro Jahr zurückgehen. Der Gewinn pro Aktie wird voraussichtlich zurückgehen um 3.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -82.9% betragen.

Wichtige Informationen

-11.6%

Wachstumsrate der Gewinne

-3.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum27.1%
Wachstumsrate der Einnahmen-13.6%
Zukünftige Eigenkapitalrendite-82.9%
Analystenabdeckung

Good

Zuletzt aktualisiert15 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

Aug 10
Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 12
The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Recent updates

Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio

Aug 30

Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

Aug 10
Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Jul 12
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Jun 13

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

May 14
Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 12
The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Apr 03

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 28
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Feb 13

Vectoring In On Verve Therapeutics

Jan 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Jun 07
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 24
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Nov 09
We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Verve Therapeutics: Cathie Wood Adds To ARKK

Sep 20

Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate

Aug 23

Verve Therapeutics falls postmarket on $200M stock offering

Jul 20

More CRISPR In Human Subjects

Jul 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

May 11
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Verve Therapeutics: Early-Stage Biotech With A Large Market

Apr 16

Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Jan 31
Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing

Aug 24

Verve Therapeutics jumps 75% in its first day of trading

Jun 17

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:VERV - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20268-234-236-2637
12/31/202513-261-233-2199
12/31/202418-221-204-17610
6/30/202421-193-134-130N/A
3/31/202416-197-150-144N/A
12/31/202312-200-159-150N/A
9/30/20238-193-154-142N/A
6/30/20235-192-173-159N/A
3/31/20233-179-152-138N/A
12/31/20222-157-136-122N/A
9/30/20221-148-127-117N/A
6/30/2022N/A-125-117-110N/A
3/31/2022N/A-137-102-96N/A
12/31/2021N/A-120-82-78N/A
9/30/2021N/A-113-69-65N/A
6/30/2021N/A-99-54-50N/A
3/31/2021N/A-53-47-44N/A
12/31/2020N/A-46-39-35N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VERV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VERV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VERV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VERVDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-13.6% pro Jahr).

Hohe Wachstumseinnahmen: VERVDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-13.6% pro Jahr).


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: VERV wird voraussichtlich in 3 Jahren unrentabel sein.


Wachstumsunternehmen entdecken